Rocket Pharmaceuticals Retained Earnings Over Time
| RCKT Stock | USD 14.39 0.19 1.34% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Rocket Pharmaceuticals Performance and Rocket Pharmaceuticals Correlation. Rocket |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Rocket Pharmaceuticals. If investors know Rocket will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Rocket Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.73) | Return On Assets (0.34) | Return On Equity (0.59) |
The market value of Rocket Pharmaceuticals is measured differently than its book value, which is the value of Rocket that is recorded on the company's balance sheet. Investors also form their own opinion of Rocket Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Rocket Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Rocket Pharmaceuticals' market value can be influenced by many factors that don't directly affect Rocket Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Rocket Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Rocket Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Rocket Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Retained Earnings Analysis
Compare Rocket Pharmaceuticals and related stocks such as Uniqure NV, Rhythm Pharmaceuticals, and Solid Biosciences LLC Retained Earnings Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| QURE | (117.3 M) | (136.7 M) | (155 M) | (198.9 M) | (220.2 M) | (276.1 M) | (396.1 M) | (467.1 M) | (535.5 M) | (659.7 M) | (784.7 M) | (455.1 M) | (581.9 M) | (890.4 M) | (845.9 M) |
| RYTM | (37 M) | (37 M) | (37 M) | (58.4 M) | (39.6 M) | (50.7 M) | (76.5 M) | (110.3 M) | (184.6 M) | (325.3 M) | (459.3 M) | (528.9 M) | (710.1 M) | (894.7 M) | (850 M) |
| SLDB | (67.7 M) | (67.7 M) | (67.7 M) | (67.7 M) | (67.7 M) | (67.7 M) | (84.9 M) | (124.3 M) | (199.1 M) | (316.3 M) | (404.6 M) | (476.8 M) | (562.7 M) | (658.8 M) | (625.8 M) |
| MGTX | (34.4 M) | (34.4 M) | (34.4 M) | (34.4 M) | (34.4 M) | (34.4 M) | (34.4 M) | (65.4 M) | (148.3 M) | (203 M) | (261 M) | (340.6 M) | (470.2 M) | (554.2 M) | (526.5 M) |
| PCVX | (29.6 M) | (29.6 M) | (29.6 M) | (29.6 M) | (29.6 M) | (29.6 M) | (29.6 M) | (29.6 M) | (59.1 M) | (109.3 M) | (198.6 M) | (298.6 M) | (522.1 M) | (924.4 M) | (878.2 M) |
| LRMR | (105.4 M) | (105.4 M) | (105.4 M) | (105.4 M) | (105.4 M) | (179.7 M) | (237.5 M) | (289.6 M) | (350.9 M) | (23.1 M) | (65.6 M) | (116.2 M) | (151.6 M) | (188.6 M) | (198 M) |
| SNDX | (79.1 M) | (79.1 M) | (79.1 M) | (135.7 M) | (159.8 M) | (259.7 M) | (305.3 M) | (366.1 M) | (439.4 M) | (495.5 M) | (568.6 M) | (543.7 M) | (693 M) | (902.4 M) | (857.3 M) |
| MRUS | (18.7 M) | (18.7 M) | (18.7 M) | (32.5 M) | (49.6 M) | (69.3 M) | (112.8 M) | (200.9 M) | (200.3 M) | (314.6 M) | (400.1 M) | (466.9 M) | (598.1 M) | (753.1 M) | (715.4 M) |
| STRO | (95.3 M) | (95.3 M) | (95.3 M) | (95.3 M) | (95.3 M) | (95.3 M) | (95.3 M) | (115 M) | (150.3 M) | (195.7 M) | (227.9 M) | (333.4 M) | (452.6 M) | (559.4 M) | (531.4 M) |
| STOK | (13.2 M) | (13.2 M) | (13.2 M) | (13.2 M) | (13.2 M) | (13.2 M) | (13.2 M) | (13.2 M) | (25.7 M) | (58 M) | (110.3 M) | (196.1 M) | (297.1 M) | (401.8 M) | (381.8 M) |
| PLRX | (36.6 M) | (36.6 M) | (36.6 M) | (36.6 M) | (36.6 M) | (36.6 M) | (36.6 M) | (36.6 M) | (71.5 M) | (76.3 M) | (117.8 M) | (215.1 M) | (338.4 M) | (499.7 M) | (474.8 M) |
| DYN | (3.2 B) | (4.8 B) | (107 M) | (463 M) | (736 M) | (686 M) | (1.9 B) | (1.9 B) | (4.9 M) | (19.7 M) | (79.2 M) | (228.5 M) | (396.6 M) | (632.5 M) | (664.1 M) |
| CYTK | (22.4 M) | (408.5 M) | (448.9 M) | (482.6 M) | (497.2 M) | (534.7 M) | (518.3 M) | (646.1 M) | (743.3 M) | (865 M) | (992.3 M) | (1.2 B) | (1.6 B) | (2.1 B) | (2 B) |
| RVMD | (67.9 M) | (67.9 M) | (67.9 M) | (67.9 M) | (67.9 M) | (67.9 M) | (67.9 M) | (67.9 M) | (109.7 M) | (157.4 M) | (265.5 M) | (452.6 M) | (701.3 M) | (1.1 B) | (1.1 B) |
| RGNX | (24.8 M) | (24.8 M) | (24.8 M) | (24.8 M) | (28.8 M) | (51.6 M) | (114.6 M) | (187.8 M) | (83 M) | (177.8 M) | (289.1 M) | (161.2 M) | (441.6 M) | (705 M) | (669.8 M) |
| DAWN | (12.8 M) | (12.8 M) | (12.8 M) | (12.8 M) | (12.8 M) | (12.8 M) | (12.8 M) | (12.8 M) | (12.8 M) | (12.8 M) | (56.8 M) | (127.5 M) | (269.7 M) | (458.6 M) | (435.7 M) |
| REPL | (9.2 M) | (9.2 M) | (9.2 M) | (9.2 M) | (9.2 M) | (9.2 M) | (9.2 M) | (28.9 M) | (59.8 M) | (112.3 M) | (193.2 M) | (311.2 M) | (485.5 M) | (701.3 M) | (666.2 M) |
| MIRM | (17.3 M) | (17.3 M) | (17.3 M) | (17.3 M) | (17.3 M) | (17.3 M) | (17.3 M) | (17.3 M) | (17.3 M) | (69.9 M) | (173.2 M) | (257.2 M) | (392.8 M) | (556.2 M) | (528.4 M) |
| VRDN | (21.4 M) | (21.4 M) | (21.4 M) | (25.9 M) | (6.6 M) | (18 M) | (30.6 M) | (93.6 M) | (126.3 M) | (168.2 M) | (278.9 M) | (358.3 M) | (488.2 M) | (725.9 M) | (689.6 M) |
| INZY | (14.9 M) | (14.9 M) | (14.9 M) | (14.9 M) | (14.9 M) | (14.9 M) | (14.9 M) | (14.9 M) | (14.9 M) | (34.7 M) | (91.1 M) | (147.7 M) | (214.8 M) | (285.9 M) | (271.6 M) |
Rocket Pharmaceuticals and related stocks such as Uniqure NV, Rhythm Pharmaceuticals, and Solid Biosciences LLC Retained Earnings description
The cumulative amount of net income that a company retains for reinvestment in its operations, rather than distributing it to shareholders as dividends.My Equities
My Current Equities and Potential Positions
| Rocket Pharmaceuticals | RCKT |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | New York; U.S.A |
| Exchange | NASDAQ Exchange |
USD 14.39
Additional Tools for Rocket Stock Analysis
When running Rocket Pharmaceuticals' price analysis, check to measure Rocket Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Rocket Pharmaceuticals is operating at the current time. Most of Rocket Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Rocket Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Rocket Pharmaceuticals' price. Additionally, you may evaluate how the addition of Rocket Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.